ADMA Biologics is a biopharmaceutical firm that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of infectious diseases and immune deficiencies globally. Its products include ASCENIV and BIVIGAM for primary humoral immunodeficiency treatment, and Nabi-HB for Hepatitis B exposure treatment. The company also runs source plasma collection facilities, and its drugs are distributed through specialty pharmacies, independent distributors, and other alternate site providers.